News

KZR-616, a selective immunoproteasome inhibitor, is safe, well-tolerated, and effectively reduces disease activity in patients with active systemic lupus erythematosus (SLE), preliminary Phase 1b data show. The findings were presented at the European League Against Rheumatism (EULAR) 2019 Annual Meeting in Geneva, Switzerland, in a poster titled, “…

These days, more than ever, we need community. As a culture, we are experiencing higher levels of stress, greater incidence of isolation, and an increase in the prevalence of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and others. Slowly, we are starting…

Certain rare gene mutations, previously ignored, appear to contribute substantially to the development of lupus, new research found, pointing to the potential for targeted therapies for the condition. The study, “Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus,” was published in …

In observance of World Lupus Day and Lupus Awareness Month, Aurinia Pharmaceuticals has announced disease awareness and educational initiatives aimed at supporting patients with lupus nephritis, a serious complication of systemic lupus erythematosus (SLE). World Lupus Day was May 10, and Lupus Awareness Month is marked…